$1.07 Billion is the total value of RTW INVESTMENTS, LP's 47 reported holdings in Q4 2018. The portfolio turnover from Q3 2018 to Q4 2018 was 54.2% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ARWR | Sell | ARROWHEAD PHARMACEUTICALS IN | $66,027,000 | -54.7% | 5,316,156 | -30.1% | 6.15% | -29.6% |
| PTCT | Sell | PTC Therapeutics Inc | $65,975,000 | -57.1% | 1,922,346 | -41.3% | 6.14% | -33.4% |
| RGNX | Sell | Regenxbio Inc | $44,058,000 | -60.0% | 1,050,245 | -28.0% | 4.10% | -37.8% |
| PRNB | Sell | Principia Biopharma Inc | $14,162,000 | -18.5% | 555,948 | -13.7% | 1.32% | +26.7% |
| VRAY | Sell | Viewray Inc | $8,280,000 | -73.9% | 1,364,156 | -59.8% | 0.77% | -59.4% |
| CDNA | Sell | CareDx Inc | $8,238,000 | -20.2% | 327,703 | -8.4% | 0.77% | +24.1% |
| PRQR | Sell | PROQR THRAPEUTICS N V | $7,072,000 | -90.2% | 448,141 | -88.0% | 0.66% | -84.8% |
| SLDB | Sell | Solid Biosciences Inc | $3,578,000 | -71.1% | 133,506 | -49.1% | 0.33% | -55.1% |
| LJPC | Sell | La Jolla Pharmaceutical Co | $2,528,000 | -89.5% | 268,036 | -77.6% | 0.24% | -83.7% |
| PTI | Sell | PROTEOSTASIS THERAPEUTICS IN | $1,016,000 | -62.7% | 313,466 | -72.2% | 0.10% | -41.7% |
| RMED | Sell | RA MED SYS INC | $487,000 | -75.7% | 61,281 | -44.3% | 0.04% | -62.5% |
| BLCM | Exit | Bellicum Pharmaceuticals Inc | $0 | – | -157,489 | -100.0% | -0.06% | – |
| NVUS | Exit | Novus Therapeutics Inc | $0 | – | -316,257 | -100.0% | -0.09% | – |
| TPIV | Exit | Tapimmune Inc | $0 | – | -209,721 | -100.0% | -0.11% | – |
| Exit | VIVUS INCnote 4.500% 5/0 | $0 | – | -4,000,000 | -100.0% | -0.19% | – | |
| NVAX | Exit | Novavax Inc | $0 | – | -2,771,023 | -100.0% | -0.31% | – |
| NVTRQ | Exit | Nuvectra Corp | $0 | – | -251,329 | -100.0% | -0.33% | – |
| VKTX | Exit | Viking Therapeutics Inc | $0 | – | -500,000 | -100.0% | -0.52% | – |
| PACB | Exit | PACIFIC BIOSCIENCES CALIF IN | $0 | – | -2,237,607 | -100.0% | -0.72% | – |
| BVX | Exit | Bovie Medical Corp | $0 | – | -2,235,547 | -100.0% | -0.95% | – |
| RMD | Exit | ResMed Inc | $0 | – | -147,400 | -100.0% | -1.02% | – |
| QGEN | Exit | Qiagen NV | $0 | – | -775,324 | -100.0% | -1.76% | – |
| ILMN | Exit | Illumina Inc | $0 | – | -82,621 | -100.0% | -1.82% | – |
| CORI | Exit | CORIUM INTL INC | $0 | – | -3,610,632 | -100.0% | -2.06% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR/A filed 2019-02-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS INC | 36 | Q3 2023 | 19.7% |
| MASIMO CORP | 32 | Q3 2023 | 5.8% |
| LA JOLLA PHARMACEUTICAL CO | 31 | Q2 2022 | 9.7% |
| REGENXBIO INC | 30 | Q4 2022 | 10.8% |
| AGENUS INC | 29 | Q2 2022 | 9.0% |
| PTC THERAPEUTICS INC | 28 | Q3 2023 | 12.8% |
| DICERNA PHARMACEUTICALS INC | 28 | Q3 2021 | 10.8% |
| MIRATI THERAPEUTICS INC | 26 | Q3 2023 | 6.2% |
| ARGENX SE | 26 | Q3 2023 | 5.3% |
| VERICEL CORP | 24 | Q3 2023 | 3.9% |
View RTW INVESTMENTS, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. | September 19, 2023 | 18,188,457 | - |
| ALLURION TECHNOLOGIES, INC. | August 11, 2023 | 3,457,707 | 7.4% |
| Orchestra BioMed Holdings, Inc. | May 05, 2023 | 5,620,645 | 15.7% |
| Renovacor, Inc.Sold out | April 05, 2023 | 0 | - |
| Adverum Biotechnologies, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Aptevo Therapeutics Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| ASLAN Pharmaceuticals LtdSold out | February 14, 2023 | 0 | 0.0% |
| Athira Pharma, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| BELLUS Health Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Clearside Biomedical, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
View RTW INVESTMENTS, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13D/A | 2024-04-17 |
| SC 13D/A | 2024-03-01 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View RTW INVESTMENTS, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.